Sign In
Buy VOR
$21.15
-0.650 (-2.98%)
At Close: Jul 31, 2026
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
04:05pm, Monday, 09'th Aug 2021
CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today reported financial results for the three-month period ended
Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia
09:28am, Thursday, 08'th Jul 2021
Vor Biopharma Inc (NASDAQ: VOR) has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ). Under the terms of the collaboration, Vor Biopharma will investigate the combin
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targ
Vor Biopharma: Targeted Therapies For Transplants
04:02pm, Wednesday, 30'th Jun 2021
Vor Biopharma: Targeted Therapies For Transplants
Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
08:00am, Friday, 11'th Jun 2021
CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies to be used in comb
Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
04:10pm, Tuesday, 25'th May 2021
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targe
Vor Reports Fiscal Year 2020 Financial Results
04:35pm, Thursday, 25'th Mar 2021
IND accepted for VOR33, Vor's lead eHSC product candidate for treatment of AML
Vor Biopharma to Present at the Barclays Global Healthcare Conference
03:00pm, Friday, 05'th Mar 2021
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies
Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
03:45pm, Monday, 01'st Mar 2021
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
04:05pm, Tuesday, 09'th Feb 2021
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies
VOR Stock Price Increased 108.33%: Why It Happened
04:06am, Monday, 08'th Feb 2021
The stock price of Vor Biopharma Inc. (NASDAQ: VOR) increased by 108.33% on Friday, February 5. This is why it happened.
U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week
02:14am, Monday, 08'th Feb 2021
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498
The Biotech IPO Wave Continues. Here Are 7 Stocks Hitting the Market.
01:28pm, Friday, 05'th Feb 2021
A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well.
Vor Biopharma's stock more than doubles out of the gate
12:18pm, Friday, 05'th Feb 2021
Shares of Vor BioPharma Inc. blasted out of the gate Friday, as they open at more the double the upsized initial public offering's price. The first trade for the Massachusetts-based cell therapy compa
